

Onxeo: report on the Extraordinary General Meeting of February 6, 2023

Paris (France), February 6, 2023 – 7:30 pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX), (“**Onxeo**” or “the **Company**”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today announced that the Extraordinary General Meeting (EGM) held today at 2 pm was able to validly deliberate with a quorum of 44.35%.

The EGM adopted all the resolutions approved by the Board of Directors.

The consolidated result of the vote by resolution and the minutes of the General Meeting will be available within the legal deadlines on the Company's website, in the [General Meetings section](#).

Next financial release

Full-year 2022 results: Thursday, March 30, 2023, after market close

About Onxeo

Onxeo (Euronext Growth Paris: ALONX) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.

platON™ is Onxeo’s proprietary chemistry platform of oligonucleotides acting as decoy agonists, which generates new innovative compounds and broaden the Company’s product pipeline.

AsiDNA, the first compound from platON, is a highly differentiated, clinical-stage first-in-class candidate in the field of DNA damage response (DDR) applied to oncology. Its decoy and agonist mechanism acting upstream of multiple DDR pathways results in distinctive antitumor properties, including the ability to prevent or abrogate tumor resistance to targeted therapies such as PARP inhibitors and strong synergy with tumor DNA-damaging agents such as radio-chemotherapy. AsiDNA is currently being studied in Europe and the US in combination with other treatment modalities in difficult-to-treat solid tumors.

OX425, the second compound from platON, is a novel DDR Decoy Agonist with high antitumor activity. It also mediates multiple immunostimulatory effects by activating the STING pathway. OX425 is currently undergoing IND-enabling preclinical development.

For further information, please visit www.onxeo.com.

Forward looking statements

This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the risk factors described in the most recent Company’s registration document or in any other periodic financial report and in any other press release, which are available free of charge on the websites of the Company Group (www.onxeo.com) and/or the AMF (www.amf-france.org).



Contacts

Onxeo

Investor Relations

investors@onxeo.com

+33 1 45 58 76 00

Media Relations

Arthur Rouillé
NewCap

onxeo@newcap.eu

+33 1 44 71 00 15

Investor Relations / Strategic Communication

Dušan Orešanský / Nicolas Fossiez
NewCap

onxeo@newcap.eu

+33 1 44 71 94 92